Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.97 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.97 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.97 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593855 | 1.00 | PRKCA (0.97) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| 1,2-Dipalmitin SCHEMBL594854 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL16431424 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8049183 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23992003 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23668326 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL1004733 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8047283 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL10426858 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7061646 | 0.98 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | claimed |
| EP-4658106-A1 | STABILIZED AEROSOL PRECURSOR FORMULATIONS | RAI Strategic Holdings, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3934753-B1 | MICROBIAL REMOVAL | CAPRETTO EHF (IS) | 2025-11-05 | — | — | EP | claimed |
| WO-2024161313-A1 | STABILIZED AEROSOL PRECURSOR FORMULATIONS | RAI STRATEGIC HOLDINGS, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | CAPRETTO EHF (IS) | 2023-04-06 | — | — | US | claimed |
| CN-111432805-B | Pharmaceutical formulations of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime | 梅克里内科尼蒂翁公司 | 2023-02-17 | — | — | CN | claimed |
| US-11337949-B2 | Thermostable formulation of biologically active substances | CAPRETTO EHF. (IS) | 2022-05-24 | — | — | US | claimed |
| US-20220152092-A1 | MICROBIAL REMOVAL | CAPRETTO EHF. (IS) | 2022-05-19 | — | — | US | claimed |
| CN-111432805-A | Pharmaceutical formulations of 3 α -ethynyl-3 β -hydroxyandrostan-17-one oxime | 梅克里内科尼蒂翁公司 | 2020-07-17 | — | — | CN | claimed |
| EP-0995430-A2 | Use of diacylolycerols for enhancing the barrier function of the skin | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0655907-B1 | USE OF DIACYLOLYCEROLS FOR INCREASING THE MELANIN CONTENT IN MELANOCYTES | UNIV BOSTON (US) | 1999-04-28 | — | — | EP | claimed |
| WO-1996009810-A1 | METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-04-04 | — | — | WO | claimed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| EP-3824296-B1 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING TESTOSTERONE TRIDECANOATE AND/OR TESTOSTERONE DODECANOATE FOR TREATING LIVER DISEASES | LIPOCINE INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12558330-B2 | Methods and compositions for treating edema refractory to oral diuretics | RESQ Pharmaceuticals LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-12539313-B2 | Microbial removal | CAPRETTO EHF. (IS) | 2026-02-03 | — | — | US | disclosed |
| WO-1996009810-A1 | METHODS FOR ENHANCING MELANIN SYNTHESIS IN MELANOCYTES USING DIACYLGLYCEROLS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5352440-A | Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 1994-10-04 | — | — | US | disclosed |
| WO-1991007167-A1 | PROTEIN KINASE ACTIVATORS AS ENHANCERS OF MELANIN PRODUCTION | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107742-A1 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | APOL1, MGLL, FABP2 | PRKCA 4472/4885PRKCE 4712/4885PRKCQ 4553/4885 |
| US-12539313-B2 | Microbial removal | CUTA, MIF, PCNA | PRKCA 2866/4885PRKCE 2153/4885PRKCQ 2296/4885 |
| US-11337949-B2 | Thermostable formulation of biologically active substances | MGLL, DAGLA, DDOST | PRKCA 2734/4885PRKCE 3153/4885PRKCQ 3450/4885 |
| US-12558330-B2 | Methods and compositions for treating edema refractory to oral diuretics | REN, AVPR2, AVPR1B | PRKCA 1560/4885PRKCE 2083/4885PRKCQ 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.